Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Update
by Doug Wharley · The Cerbat GemCocrystal Pharma, Inc. (NASDAQ:COCP – Get Free Report) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totaling 160,347 shares, a growth of 22.0% from the December 31st total of 131,425 shares. Based on an average daily volume of 101,779 shares, the days-to-cover ratio is presently 1.6 days. Currently, 1.6% of the shares of the company are short sold. Currently, 1.6% of the shares of the company are short sold. Based on an average daily volume of 101,779 shares, the days-to-cover ratio is presently 1.6 days.
Cocrystal Pharma Price Performance
NASDAQ COCP opened at $0.96 on Thursday. Cocrystal Pharma has a 12 month low of $0.90 and a 12 month high of $2.67. The firm has a market capitalization of $13.23 million, a PE ratio of -1.02 and a beta of 1.20. The company’s 50 day simple moving average is $1.03 and its 200 day simple moving average is $1.23.
Cocrystal Pharma (NASDAQ:COCP – Get Free Report) last released its earnings results on Friday, November 14th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.03. Sell-side analysts anticipate that Cocrystal Pharma will post -1.85 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cocrystal Pharma in a research report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $6.00.
Get Our Latest Stock Analysis on COCP
Insider Buying and Selling at Cocrystal Pharma
In other Cocrystal Pharma news, Director Phillip Md Et Al Frost acquired 50,000 shares of Cocrystal Pharma stock in a transaction dated Wednesday, December 31st. The stock was acquired at an average cost of $0.95 per share, for a total transaction of $47,500.00. Following the completion of the transaction, the director owned 1,838,551 shares in the company, valued at approximately $1,746,623.45. This represents a 2.80% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders purchased a total of 159,000 shares of company stock worth $152,710 over the last quarter. Insiders own 28.14% of the company’s stock.
About Cocrystal Pharma
Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.
The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.